Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.26, $0.05 better than the analyst estimate of $1.21. Revenue for the quarter came in at $135.5 million versus the consensus estimate of $138.41 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.